Study Design and Methods The authors investigated three prostate cancer cell lineshuman androgen receptor (AR)-positive 22Rv1, AR-negative DU145, and murine Myc-CaPtreated with recombinant IGF-1 (30 nM for 24 h)
[1] In the bloodstream, more than 95% of circulating IGF-1 is not free
doi: 10.1016/S0006-2952(02)01257-1
SPF 30 Mineral Protection Broad-spectrum sun defense without the white cast.
This trial, while not showing superiority of JTA-004 over placebo in the overall population, provides highly valuable insights into clinical trial design, placebo responses, and the potential need for better patient stratification in osteoarthritis research
Judge Marston addressed case census, discovery schedules, selection of lead counsel, complaint amendments, and future status conferences